David Fredrickson, Executive Vice-President of Oncology Business at AstraZeneca, shared a post on LinkedIn:
“What a privilege to join the Milken Institute and the Richard Nixon Foundation for their Cancer 2035 event this week that gathered top cancer experts across sectors to envision the future of care. There was a great deal of optimism around how fast science and technology are accelerating progress, and a spirit of true collaboration in the room.
A few takeaways from the truly top-notch speakers that are sticking with me:
- Richard Pazdur noted that when it comes to accelerating progress with clinical trials, we can sometimes be our own worst enemy – adding complexity and bureaucracy when we need to make it easy and simplify.
- Ed Kim reminded us that one of the most altruistic acts a patient can do is participate in a clinical trial for the good of the broader patient community – it is not a privilege. The critical question is how we can enable this altruistic act as much as possible.
- George yancopoulos urged us to catch-up with the tech sector when it comes to data. One key is having enormous and constantly updated datasets to make progress at pace using AI.
- And Clifford Hudis shared a great analogy for what the future of clinical decision support will look like in cancer for doctors. One day in the not-too-distant future it will be just like lane assist in your car – you won’t even know you are using AI, it will just gently nudge you in the right direction toward guideline-based care.
- When talking about the future of collaboration, we considered how best to facilitate and empower like-minded companies and organizations pursuing the same goals to work together for patients. Karen Knudsen MBA PhD suggested a brilliant idea – we need a Match.com equivalent for public-private partnerships.
- And Noubar Afeyan really inspired me with his message of how to pursue scientific leaps of faith: we have to be unreasonable, and our only limitation is our imagination.
- There are so many opportunities to improve and democratize high-quality care for patients with cancer if we act with urgency. The real imperative now is bringing stakeholders together across the ecosystem to create the conditions to consistently and sustainably translate breakthroughs into better patient outcomes. Progress at scale will only happen if we work in concert. None of us can do this alone.
Congratulations Esther Krofah, Mike Milken and team on an outstanding event and huge thanks for the opportunity to participate.”
Other articles featuring David Fredrickson on OncoDaily.
